AI Article Synopsis
- The study aimed to evaluate the effectiveness of modified Longdan Xiegan Decoction (LXD) for treating hyperandrogenism in women with polycystic ovary syndrome (POS) categorized as stagnant fire in the Gan channel type.
- Patients were divided into two groups, with one receiving LXD and the other Diane-35, and both treatments were assessed for improvements in menstrual disorders, acne, and hormonal levels over three months.
- Results showed that while both treatments led to significant improvements, the LXD group had a notably lower level of prolactin and reported no adverse reactions, suggesting it could be a safer alternative for these patients.
Article Abstract
Objective: To observe the therapeutic effect of modified Longdan Xiegan Decoction (LXD) on hyperandrogenism in patients with polycystic ovary syndrome (POS) of stagnant fire in Gan channel type.
Methods: Forty-eight patients were divided into two groups: the LXD group (25 cases) treated with LXI) for 3 months, and the Diane-35 group (23 cases) with Diane-35. Condition of menstruation, acne, hairiness were observed, basal body temperature (BBT) was measured, and the serum levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH), prolactin (PRL), free testosterone (FT), and androstenedione (A) were detected before and after 3 months' treatment. Meanwhile, adverse reaction was observed.
Results: After treatment, the condition of menstrual disorder, acne and single-phase BBT were improved significantly, and serum levels of LH, LH/FSH, FT and A decreased in both groups (P < 0.05), showed insignificant difference between them (P > 0.05). The PRL level dropped in the LXD group (P < 0.05), which significantly lower than that in the Diane-35 group (P < 0.05). There were 3 cases with adverse reaction of irregular colporrhagia and 5 cases with nausea and vomiting in the Diane-35 group, while no adverse reaction in the LXD group occurred.
Conclusion: Modified LXD could significantly improve the condition in hyperandrogenism patients with POS of stagnant fire in Gan channel type.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Purpose: Polycystic Ovary Syndrome (PCOS) and Adrenal hyperplasia (CAH) are two pathologic conditions sharing several clinical features (hirsutism, acne, polycystic ovary morphology, metabolic alterations, ovulatory dysfunctions) and especially hyperandrogenism as a common clinical hallmark. Therefore, making a differential diagnosis of the two conditions still remains a great medical challenge.
Methods: In particular, the comparison discussed in this review referred to non-classical form of adrenal hyperplasia (NCAH), which regards the adult population, and the Endocrine Metabolic Syndrome (EMS), following the new set of PCOS diagnostic criteria proposed by the Experts Group on Inositol and Clinical Research, and on PCOS (EGOI-PCOS).
Polycystic ovary syndrome negatively affects sexual function and lower urinary tract symptoms in syrian women: a case-control study.
Sci Rep
January 2025
Department of Surgery, Faculty of Medicine, Damascus University, Damascus, Syrian Arab Republic.
Polycystic ovary syndrome (PCOS) is the most prevalent endocrine disorder in women of reproductive age worldwide, and its related features like obesity, mental health issues and hyperandrogenism may contribute to inadequately investigated health problems such as sexual dysfunction (SD) and lower urinary tract symptoms (LUTS). Therefore, this study examined the impact of PCOS on sexual function (SF) and lower urinary tract in Syrian women by recruiting a total of 178 women of reproductive age, of whom 88 were diagnosed with PCOS according to the Rotterdam criteria and 90 without PCOS were considered as the control group. Female sexual function index (FSFI) and Bristol Female Lower Urinary Tract Symptom Questionnaire (BFLUTS) were used to assess SF and LUTS respectively.
View Article and Find Full Text PDF[Polycystic Ovary Syndrome and Mental Health in Adolescents].
Andes Pediatr
October 2024
Facultad de Medicina Occidente, Universidad de Chile, Santiago, Chile.
Article Synopsis
- Polycystic Ovary Syndrome (PCOS) is the most common endocrine disorder in female adolescents, leading to various health issues, including metabolic and psychiatric problems.
- Recent studies indicate a higher risk of mental health disorders like anxiety, depression, and eating disorders in women with PCOS, and potential neurodevelopmental risks for their children as well.
- The underlying causes for these mental health associations are not fully understood yet, emphasizing the need for better mental health assessments and collaboration among healthcare providers in managing PCOS.
Generation of a human induced pluripotent stem cell line NTUHi006-A from a polycystic ovarian syndrome patient.
Stem Cell Res
December 2024
Department of Obstetrics and Gynecology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan; Livia Shangyu Wan Chair Professor of Obstetrics and Gynecology, National Taiwan University, Taipei, Taiwan Research Center for Cell Therapy and Regeneration Medicine, Taipei Medical University, Taipei, Taiwan. Electronic address:
Polycystic ovary syndrome (PCOS) is a common endocrine disorder related to multifactors and genetic polymorphisms. Here, we derived an induced pluripotent stem cell (hiPSC) line NTUHi006-A from a phenotype A (full-blown) PCOS patients with clinical hyperandrogenism, chronic anovulation, and polycystic ovarian morphology on ultrasonography. NTUHi006-A showed stemness, pluripotency and stem cell-like morphology.
View Article and Find Full Text PDFPrevalence of Intersex/Differences in Sex Development and Primary Gonadal Insufficiency in a Pediatric Transgender Population.
Transgend Health
December 2024
University of Missouri-Kansas City School of Medicine, Kansas City, Missouri, USA.
Purpose: This study aims to assess the prevalence of intersex variations/differences in sex development (I/DSDs), associated adrenal conditions, and primary gonadal insufficiency in children with gender dysphoria.
Methods: We performed a comprehensive review of the medical records for individuals who carried the diagnostic codes for gender dysphoria in addition to intersex and/or other conditions associated with sex steroid variations among patients evaluated by pediatric endocrinologists from 2013 to 2022.
Results: We found that 9 of 612 (1.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!